We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
According to sources in Cuba's state-run media, the government is testing a new biotech drug that is reportedly effective in slowing cancer cell replication.
French health spending increased only marginally in the first seven months of the year, growing 3.5% to reach EUR64.30bn (US$79.81bn), as government cost-containment measures began to take effect.
Foreign multinationals are increasingly outsourcing research and development to low-cost developing countries such as India and China in the face of growing pressures in their home markets.
Celera Diagnostics, a joint venture between the Celera Genomics Group (NYSE:CRA) and Applied Biosystems Group (NYSE:ABI) of Applera Corporation, today announced the extension of its collaboration with Merck & Co., Inc. aimed at developing new treatments for Alzheimer's disease.
Novo Nordisk A/S and Sangamo BioSciences, Inc. today announced an agreement that provides Novo Nordisk with access to Sangamo's proprietary zinc finger DNA-binding protein (ZFP) technology.
SkyePharma PLC (Nasdaq: SKYE; LSE: SKP) announces today that its partner Novartis Pharma AG (Novartis) has launched FORADIL(R) CERTIHALER(TM) (formoterol fumarate inhalation powder) on the German market for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
In a surprising and legally risky move, Barr Pharmaceuticals and a partner launched generic versions of the blockbuster allergy pill Allegra despite patents remaining on the prescription drug.
Holmes Herbs, Inc., (OTCBB:HMHB), announced today that it has entered into an agreement to purchase a controlling interest in Qualia Clinical Research Services Ltd. ("Qualia").
Drugmaker Novartis unveiled a research alliance with U.S.-based Alnylam Pharmaceuticals worth up to $700 million and aimed at a hot field of gene therapy called RNA interference, or RNAi.